Su W.-J.MING-CHIH HOYEN-HSUAN NIHUEY-LING CHENREY-HENG HUYAO-MING WUMEI-HWEI CHANGPO-HUANG LEE2021-01-042021-01-0420090277-2116https://www.scopus.com/inward/record.uri?eid=2-s2.0-66149139468&doi=10.1097%2fMPG.0b013e3181819ad4&partnerID=40&md5=6b3d7744f456be392a7af36975f906c8https://scholars.lib.ntu.edu.tw/handle/123456789/537035OBJECTIVE[SDGs]SDG3corticosteroid; cyclosporin; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; hepatitis B vaccine; hepatitis C antibody; tacrolimus; antivirus agent; hepatitis B antibody; hepatitis B core antigen; hepatitis B surface antigen; hepatitis B vaccine; adolescent; allograft; antibody titer; article; child; corticosteroid therapy; de novo hepatitis B; drug blood level; female; follow up; graft recipient; hepatitis B; human; immunosuppressive treatment; incidence; infant; infection risk; liver function test; liver graft rejection; liver transplantation; major clinical study; male; preoperative evaluation; preoperative treatment; priority journal; Taiwan; vaccination; blood; graft survival; hepatitis B; immunology; preschool child; recurrent disease; risk factor; Hepatitis B virus; Hepatitis C virus; Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Graft Survival; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Humans; Incidence; Infant; Liver Transplantation; Male; Recurrence; Risk Factorsjournal article10.1097/MPG.0b013e3181819ad4191798832-s2.0-66149139468